Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss
This study has suspended participant recruitment.
(Restructuring of Cell Lab)
CBR Systems, Inc.
Information provided by (Responsible Party):
First received: January 8, 2014
Last updated: August 10, 2016
Last verified: August 2016
To determine if autologous human umbilical cord blood infusion in children with acquired hearing loss is safe, feasible, improves inner ear function, audition and language development.
Sensorineural Hearing Loss
Genetic: Autologous Stem Cells
||Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss
Primary Outcome Measures:
- Safety of Autologous Stem Cell Infusion [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
To determine if autologous human umbilical cord blood (hUBC) infusion in children with hearing loss is safe and feasible. Infusion related toxicity as measured by:
i. hemodynamic instability: An adverse event will be defined as a sustained (> 10 minutes) >20% decrease in MAP.
ii. acute lung injury: Chest X-ray will be done at baseline and at 1 day post infusion to assess for polymorphonuclear infiltrates iii. hepatic injury/toxicity: Hepatic panel will be performed at baseline and 1 day post infusion. Injury is defined as acute elevation of the AST/ALT hepatic enzymes > 900 U/dl in the first 24 hours post infusion iv. renal injury/insufficiency: CMP will be performed at baseline and 1 day after infusion v. exacerbation of neurological status: defined as a change in Glasgow Coma Scale, pupillary size/reactivity, motor/sensory evaluation of extremities, and seizure activity from infusion to discharge.
Secondary Outcome Measures:
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||January 2017 (Final data collection date for primary outcome measure)
Experimental: Autologous Stem Cells
A single dose of intravenously administered autologous hUCB will be done. The minimum acceptable dose will be 6x10 6th mononuclear cells/kilogram body weight. The hUCB reanimation, cell processing and product infusion will occur at Florida Hospital for Children and the Florida Hospital Center for Cellular Therapy.
Genetic: Autologous Stem Cells
The subjects autologous stem cells banked at Cord Blood Registry will be infused intravenously by gravity.
Other Name: Cell based therapy
There is currently no treatment available to repair/reverse acquired sensorineural hearing loss. Recent experiments using human umbilical cord blood treatment of a mouse and guinea pig models have demonstrated hair cell re-growth following acquired sensorineural loss as well as partial restoration of ABR. Autologous human umbilical cord blood therapy, which has been used for over twenty years, has an excellent safety record. This study will determine if autologous human umbilical cord blood infusion in children with hearing loss is safe and feasible, improves inner ear function, audition, and language development. The patients umbilical cord stem cells collected at birth and stored at Cord Blood Registry will be used for infusion.
|Ages Eligible for Study:
||6 Weeks to 6 Years (Child)
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Evidence of a sensorineural hearing loss
- Unilateral or bilateral in configuration
- Symmetrical or asymmetrical configuration
- Sudden or progressive in presentation
- Moderate to profound in degree (40-90 Decibels (dB) in at least one ear
- Normally shaped cochlea, as determined by MRI
The loss must be considered:
- Unknown with a negative genetic test.
- Fitted for hearing aids no later than six months post detection of loss.
- Enrollment in a parent/child intervention program
- Age 6 weeks - 6 years old at time of infusion with less than 18 months of hearing loss at the time of cord blood infusion.
- Ability of the child and caregiver to travel to Orlando, and stay for at least 4 days, and to return for all follow-up visits.
Inability to obtain all pertinent medical records:
- (pertinent physician notes, speech language pathology notes, laboratory findings, test results and imaging studies-must be sent to the research team at least prior to the subject arriving at the study location for preliminary screening and eligibility assessment, preferably14 days before the scheduled hUBC treatment.)
Known history of:
- Recently treated infection less than 2 weeks before infusion.
- Renal disease of altered renal function as defined by serum creatinine > 1.5 mg/dl at admission.
- Hepatic disease or altered liver function as defined by SGPT > 150 U/L, and or T. Bilirubin > 1.3 mg/dL
- Immunosuppression as defined by WBC < 3,000 at admission
- Human Immunodeficiency Virus (HIV)
- Hepatitis B
- Hepatitis C
- Evidence of an extensive stroke (> 100ml lesion)
- Pneumonia, or chronic lung disease requiring oxygen
- Genetic syndromic sensorineural hearing loss
- hUBC sample contamination
- Banked cord cells totaling less than 6x106 mononuclear cells/kilogram body weight.
- Evidence of the following maternal infections during the pregnancy (Hepatitis A, Hepatitis B, Hepatitis C, HIV 1, HIV 2, Human T-lymphotropic Virus (HTLV) 1, HTLV 2 (CMV and Syphilis can be included in the study)
- participation in a concurrent intervention study
- Unwillingness or inability to stay for 4 days following hUBC infusion (should problems arise following the infusion) and to return for the one month, six month and one year follow-up visits.
- Presence of a cochlear implantation device
- Evidence of a genetic syndrome
- Evidence of conductive hearing loss
- Documented recurrent middle ear infections which are frequent (>5 per year)
- Otitis media at the time of examination
- Sensorineural loss is mild
- Over 18 months from identification of hearing loss at time of infusion
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02038972
|Orlando, Florida, United States, 32803 |
CBR Systems, Inc.
||James Baumgartner, MD
History of Changes
|Other Study ID Numbers:
|Study First Received:
||January 8, 2014
||August 10, 2016
||United States: Food and Drug Administration
|Individual Participant Data
|Plan to Share IPD:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 21, 2016
Hearing Loss, Sensorineural
Nervous System Diseases
Signs and Symptoms